- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05048368
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
A Pharmacokinetic Study of Larotinib in Subjects With Mild/Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A phase I, a single-center, non-randomized, open, single-dose administration study to explore the safety, pharmacokinetics of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects with normal hepatic function.
This study is divided into four cohorts, cohort A and cohort C in healthy subjects, cohort B for mild hepatic function impairment participants, cohort D for moderate hepatic function impairment, participants in cohort A and cohort B, group C and group D should be matched in terms of sex, age, and body mass index (BMI). A total of 32 subjects, 8 in each cohort, both male and female, are planned to be enrolled. If a complete PK blood sample is not collected due to subjects' early withdrawal from the study, new subjects will be enrolled to meet the pharmacokinetic parameters that can be evaluated for each cohort of 8 subjects.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jia Miao, MD
- Phone Number: +86 18980601806
- Email: miaosiyi1971@163.com
Study Contact Backup
- Name: Hong Tang, MD
- Phone Number: +86 18980601313
- Email: Htang6198@hotmail.com
Study Locations
-
-
Sichuan
-
Chendu, Sichuan, China, 610041
- West China Hospital of Sichuan University
-
Contact:
- Jia Miao, MD
- Phone Number: +86 18980601806
- Email: miaosiyi1971@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- healthy subjects with normal hepatic function (cohorts A and C) :
- 1. Sign the informed consent form before the trial;
- 2. subjects and must be 18 to 70 years of age inclusive, Male or female. body weight >50 kg (male) or ≥45 kg (female) at screening. (BMI) : 18-30 kg/m^2, (including critical value) [BMI= weight (kg)/height^2 (m^2)] (BMI matching ±15% with liver dysfunction cohort);
- 3.Must be in good health as determined by past medical history, physical examination, vital signs, ECG, and laboratory tests at Screening;
- 4.Subjects (including partners) have no pregnancy plan within 6 months after the last dose of study drug and voluntarily take effective contraceptive measures.
- Subjects with mild/ Moderate hepatic Impairment (cohorts B and D) :
- 1. Sign the informed consent form before the trial.
- 2. subjects and must be 18 to 70 years of age inclusive, Male or female. body weight >50 kg (male) or ≥45 kg (female) at screening. (BMI) : 18-30 kg/m^2;
- 3. Must satisfy the criteria for hepatic Impairment as evidenced by a Child-Pugh class of A or B at Screening:Class A; Mild; Child-Pugh score 5-6;Class B; Moderate; Child-Pugh score 7-9
- 4. The liver function status of the subjects was determined to be stable between 1 month before taking the experimental drug and the end of the study, with no significant change.
- 5. Subjects (including partners) have no pregnancy plan within 6 months after the last dose of study drug and voluntarily take effective contraceptive measures.
Exclusion Criteria:
- ALL subjects
- 1. The subject has been diagnosed with acquired immune deficiency syndrome (AIDS), or tests positive for human immunodeficiency virus (HIV).
- 2. Currently suffering from any bleeding disease, such as gastric and duodenal ulcer
- 3. Those who had undergone major surgery within 6 months before the screening period or the surgical incision did not completely heal;
- 4. History of hand foot syndrome;
- 5. Those who have a history of liver cancer or other malignant tumors before signing the informed consent
- 6. Those who have a history of gastrointestinal and renal diseases or surgery that may affect drug absorption, distribution, metabolism and excretion within 6 months before screening, or have diseases that can reduce compliance
- 7. Take any food or beverage products containing alcohol, caffeine, xanthine and grapefruit within 48 hours prior to the first dose.
- 8. The subject has received blood within 1 month, or donated loss of blood over 400 mL within 3 months prior to the screening
- 9. Have a history of alcoholism or positive alcohol breath test during the screening period;
- 10. Those who smoke more than 5 cigarettes a day or habitually use nicotine containing products 3 months before screening
- 11. Those who had a history of drug abuse or used drugs within 2 years before screening or those who were positive for urinary drug screening during the screening period Allergic constitution
- 12. Allergic constitution
- 13. Within 28 days before screening, inhibitors or inducers of CYP3A4, cyp2c8, CYP2C19 and P-gp were used
- 14. Participated in any other intervention clinical trial within 3 months before screening
- 15. Female subjects with positive pregnancy test results or breastfeeding during screening;
- 16. Any other circumstances that the investigator considers unsuitable for participation in this study
- The following exclusion criteria apply only to healthy subjects with normal hepatic function (cohorts A and C) :
- 17. he subject has evidence of clinically significant cardiovascular, GI, renal, respiratory, endocrine, hematological, neurological, or psychiatric disease or abnormalities.
- 18. The subject tests positive for HBsAg or Hepatitis C antibody
- 19. The subject has used any prescription or nonprescription drugs within 2 weeks prior to the screening.
- The following exclusion criteria apply only to subjects with mild/ Moderate hepatic Impairment (cohorts B and D) :
- 17. The following exclusion criteria apply only to subjects with liver function impairment (cohorts B and D) :
- a) ALT>10×ULN;
- b) AST> 10×ULN;
- c) Absolute count of neutrophils <0.75×10^9/L;
- d) PLT<50×10^9/L
- e) HGB<60 g/L
- f) AFP >100 ng/mL; If 20 ng/mL≤AFP≤100 ng/mL, liver MRI are required to exclude subjects with suspected HCC.
- g) eGFR<60 mL/min/1.73m^2.
- h) Male:QTcF> 450 msec,Female:QTcF>470 msec。
- 18. The subject has any of the following conditions: Diseases affecting bile excretion such as biliary obstruction; Drug induced liver injury; History of liver transplantation; Liver failure, or liver cirrhosis patients with complications such as hepatic encephalopathy, rupture and bleeding of esophageal and gastric varices, etc; Patients with severe or advanced peritoneal effusion or pleural effusion need puncture drainage and albumin supplementation. Patients with hepatorenal syndrome.
- 19. Previous severe esophagogastric varices or previous portosystemic shunt, including transjugular intrahepatic portosystemic shunt (TIPS)
- 20. Cardiovascular events occurred within 6 months before screening
- 21. Those who use prescription drugs, over-the-counter drugs, Chinese herbal medicine or food supplements other than drugs for the treatment of liver function impairment and other accompanying diseases within 14 days before screening;
- 22. Medical conditions which are not adequately and stably controlled on stable doses of medications or which, in the clinical opinion of the Principal Investigator, may interfere with study procedures or participant safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A-Larotinib
Cohort A:Healthy participants with normal hepatic function (match to subjects with mild hepatic impairment_cohort B)
|
Capsules, Oral, 350 mg, single dose, one day
|
Experimental: Cohort B-Larotinib
Subjects with mild hepatic impairment
|
Capsules, Oral, 350 mg, single dose, one day
|
Experimental: Cohort C-Larotinib
Healthy participants with normal hepatic function (match to subjects with moderate hepatic impairment_cohort D)
|
Capsules, Oral, 350 mg, single dose, one day
|
Experimental: Cohort D-Larotinib
Subjects with moderate hepatic impairment.
|
Capsules, Oral, 350 mg, single dose, one day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: Day 1 to Day 7
|
Maximum plasma concentration of study drugs
|
Day 1 to Day 7
|
Area Under Curve From 0 to Infinity (AUC0-infinity)
Time Frame: Day 1 to Day 7
|
AUC0-infinity represents the area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity
|
Day 1 to Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event
Time Frame: Day-7 to Day 14
|
New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
|
Day-7 to Day 14
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Z650-HI-105
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Cancer
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
National Cancer Institute (NCI)NRG OncologyCompletedEsophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7United States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedEsophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer NosGermany
-
University of Wisconsin, MadisonActive, not recruitingResectable Esophageal Cancer | GastroEsophageal CancerUnited States
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsNot yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
Tianjin Medical University Cancer Institute and...UnknownStage III Esophageal Cancer | Stage II Esophageal CancerChina
-
Cancer Institute and Hospital, Chinese Academy...Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital...UnknownEsophageal Neoplasm | Esophageal Cancer TNM Staging Primary Tumor (T) T3 | Esophageal Cancer TNM Staging Primary Tumor (T) T2 | Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0 | Esophageal Cancer TNM Staging Distal Metastasis (M) M0China
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC UtrechtCompletedEsophageal Cancer, Stage II | Esophageal Cancer Stage IIINetherlands
-
Tianjin Medical University Cancer Institute and...The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsUnknownEsophageal Cancer Stage III | Esophageal Cancer Stage IIBChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7 | Malignant Neoplasm of the Cervical Esophagus | Malignant Neoplasm...United States
Clinical Trials on Larotinib
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Sunshine Lake Pharma Co., Ltd.CompletedEsophageal Squamous Cell CarcinomaChina
-
Sunshine Lake Pharma Co., Ltd.TerminatedPancreatic CancerChina
-
Peking Union Medical CollegePeking University Hospital of StomatologyRecruitingPrecision Therapy | Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma | Neoadjuvant or Conversion TherapyChina
-
Sunshine Lake Pharma Co., Ltd.Active, not recruiting